The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases

CT Chou, Hsien-Tzung Liao, CH Chen, WS Chen, HP Wang, KY Su

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.

Original languageEnglish
Pages (from-to)165-71
Number of pages7
JournalBiomarker Insights
Volume2
Publication statusPublished - 2007

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases'. Together they form a unique fingerprint.

  • Cite this

    Chou, CT., Liao, H-T., Chen, CH., Chen, WS., Wang, HP., & Su, KY. (2007). The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. Biomarker Insights, 2, 165-71.